BronchogenvsMOTS-C

Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.

For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.

As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.

MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded in the mitochondrial genome within the 12S rRNA gene. Its discovery in 2015 by Dr. Changhan David Lee at USC was groundbreaking because it demonstrated that the mitochondrial genome encodes functional peptides beyond the 13 oxidative phosphorylation subunits traditionally recognized — establishing mitochondria as endocrine organelles capable of producing signaling hormones.

MOTS-C's primary metabolic mechanism centers on activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. MOTS-C activates AMPK by increasing the AMP/ATP ratio through inhibition of the folate cycle and de novo purine biosynthesis pathway. Specifically, MOTS-C inhibits the folate/methionine cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase), leading to accumulation of the intermediate AICAR — which is itself an endogenous AMPK activator. This creates a feed-forward AMPK activation signal.

Activated AMPK triggers a cascade of metabolic adaptations that mimic exercise: increased glucose uptake via GLUT4 translocation (independent of insulin signaling), enhanced fatty acid oxidation through ACC phosphorylation and CPT-1 activation, stimulation of mitochondrial biogenesis via PGC-1α, and suppression of mTORC1-mediated protein synthesis to conserve energy. Under metabolic stress, MOTS-C translocates from the cytoplasm to the nucleus — a remarkable feat for a mitochondria-encoded peptide — where it directly regulates nuclear gene expression by interacting with antioxidant response elements (AREs) and NF-κB target genes. This nuclear translocation represents a novel mechanism of mitonuclear communication — the mitochondria literally sending a peptide messenger to the nucleus to coordinate the cellular stress response. MOTS-C levels decline with age in humans, correlating with the age-related decline in metabolic fitness, insulin sensitivity, and exercise capacity, making it a compelling target for metabolic aging intervention.